Linahenz M OD 1000mg/5mg Tablet ER

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. This combination is indicated for the management of type 2 diabetes mellitus in adults when diet and exercise alone do not provide adequate glycemic control. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release Metformin.

Linahenz M OD should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is recommended during therapy. This medication is not indicated for type 1 diabetes or diabetic ketoacidosis. Linahenz M OD 1000mg/5mg Tablet ER offers a synergistic approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.